Overview of animal models of idiopathic inflammatory myopathy-associated interstitial lung disease

doi:10.11958/20231796

Abstract

Abstract:

Idiopathic inflammatory myopathy (IIM) is a heterogeneous autoimmune disease of unknown etiology characterized by proximal limb muscle involvement and chronic inflammation. Multiple systems may be involved, with interstitial lung disease (ILD) being the most common manifestation of respiratory system involvement in IIM. This article summarizes the current methods of myositis animal models and myositis-associated ILD model construction methods, so as to provide reference for the subsequent construction and research of IIM-ILD models.

Key words: polymyositis, lung diseases, interstitial, models, animal, review

CLC Number:

R966

References 31

[1]	LUNDBERG I E, FUJIMOTO M, VENCOVSKY J, et al. Idiopathic inflammatory myopathies[J]. Nat Rev Dis Primers, 2021, 7(1):86. doi:10.1038/s41572-021-00321-x.
[2]	FINDLAY A R, GOYAL N A, MOZAFFAR T. An overview of polymyositis and dermatomyositis[J]. Muscle Nerve, 2015, 51(5):638-656. doi:10.1002/mus.24566.
[3]	MAHLER M, MILLER F W, FRITZLER M J. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review[J]. Autoimmun Rev, 2014, 13(4-5):367-371. doi:10.1016/j.autrev.2014.01.022.
[4]	SCHMIDT J. Current classification and management of inflammatory myopathies[J]. J Neuromuscul Dis, 2018, 5(2):109-129. doi:10.3233/JND-180308.
[5]	LUNDBERG I E, TJÄRNLUND A, BOTTAI M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups[J]. Ann Rheum Dis, 2017, 76(12):1955-1964. doi:10.1136/annrheumdis-2017-211468.
[6]	YE S, CHEN X X, LU X Y, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease:a retrospective cohort study[J]. Clin Rheumatol, 2007, 26(10):1647-1654. doi:10.1007/s10067-007-0562-9.
[7]	DAWKINS R L. Experimental myositis associated with hypersensitivity to muscle[J]. J Pathol Bacteriol, 1965, 90(2):619-625. doi:10.1002/path.1700900231.
[8]	MATSUBARA S, OKUMURA S. Experimental autoimmune myositis in SJL/J mice produced by immunization with syngeneic myosin B fraction. Transfer by both immunoglobulin G and T cells[J]. J Neurol Sci, 1996, 144(1/2):171-175. doi:10.1016/s0022-510x(96)00223-7.
[9]	KANG J, ZHANG H Y, FENG G D, et al. Development of an improved animal model of experimental autoimmune myositis[J]. Int J Clin Exp Pathol, 2015, 8(11):14457-14464.
[10]	SUGIHARA T, SEKINE C, NAKAE T, et al. A new murine model to define the critical pathologic and therapeutic mediators of polymyositis[J]. Arthritis Rheum, 2007, 56(4):1304-1314. doi:10.1002/art.22521.
[11]	ZHANG S, JIA X, ZHANG Q, et al. Neutrophil extracellular traps activate lung fibroblast to induce polymyositis-related interstitial lung diseases via TLR9-miR-7-Smad2 pathway[J]. J Cell Mol Med, 2020, 24(2):1658-1669. doi:10.1111/jcmm.14858.
[12]	LAYOUN H, HAJAL J, SALIBA Y, et al. Pirfenidone mitigates TGF-β1-mediated fibrosis in an idiopathic inflammatory myositis-associated interstitial lung disease model[J]. Cytokine, 2022,154:155899. doi:10.1016/j.cyto.2022.155899.
[13]	KOHYAMA K, MATSUMOTO Y. C-protein in the skeletal muscle induces severe autoimmune polymyositis in Lewis rats[J]. J Neuroimmunol, 1999, 98(2):130-135. doi:10.1016/s0165-5728(99)00087-9.
[14]	KAMIYA M, MIZOGUCHI F, YASUDA S. Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis[J]. J Cachexia Sarcopenia Muscle, 2022, 13(4):2118-2131. doi:10.1002/jcsm.13025.
[15]	BOWLES N E, DUBOWITZ V, SEWRY C A, et al. Dermatomyositis, polymyositis, and Coxsackie-B-virus infection[J]. Lancet, 1987, 1(8540):1004-1007. doi:10.1016/s0140-6736(87)92271-9.
[16]	TARIQ N, KYRIAKOPOULOS C. Group B Coxsackie Virus. In:StatPearls. Treasure Island(FL): StatPearls Publishing, 2023.
[17]	AFZALI A M, RUCK T, WIENDL H, et al. Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?[J]. Autoimmun Rev, 2017, 16(5):478-494. doi:10.1016/j.autrev.2017.03.001.
[18]	NALBANDIAN A, LLEWELLYN K J, BADADANI M, et al. A progressive translational mouse model of human valosin-containing protein disease:the VCP(R155H/+) mouse[J]. Muscle Nerve, 2013, 47(2):260-270. doi:10.1002/mus.23522.
[19]	KINDER T B, HEIER C R, TULLY C B, et al. Muscle weakness in myositis: microRNA-mediated dystrophin reduction in a myositis mouse model and human muscle biopsies[J]. Arthritis Rheumatol, 2020, 72(7):1170-1183. doi:10.1002/art.41215.
[20]	CHAKRABARTI S, KOBAYASHI K S, FLAVELL R A, et al. Impaired membrane resealing and autoimmune myositis in synaptotagmin VII-deficient mice[J]. J Cell Biol, 2003, 162(4):543-549. doi:10.1083/jcb.200305131.
[21]	OKIYAMA N, ICHIMURA Y, SHOBO M, et al. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis[J]. Ann Rheum Dis, 2021, 80(9):1201-1208. doi:10.1136/annrheumdis-2020-218661.
[22]	KATSUMATA Y, RIDGWAY W M, ORISS T, et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation[J]. J Autoimmun, 2007, 29(2/3):174-186. doi:10.1016/j.jaut.2007.07.005.
[23]	SOEJIMA M, KANG E H, GU X, et al. Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis[J]. Arthritis Rheum, 2011, 63(2):479-487. doi:10.1002/art.30113.
[24]	AYILYA B L, BALDE A, RAMYA M, et al. Insights on the mechanism of bleomycin to induce lung injury and associated in vivo models:A review[J]. Int Immunopharmacol, 2023,121:110493. doi:10.1016/j.intimp.2023.110493.
[25]	WILFONG E M, AGGARWAL R. Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease[J]. Ther Adv Musculoskelet Dis, 2021,13:1759720X211060907. doi:10.1177/1759720X211060907.
[26]	GONO T, KANEKO H, KAWAGUCHI Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease[J]. Rheumatology (Oxford), 2014, 53(12):2196-2203. doi:10.1093/rheumatology/keu258.
[27]	ZHANG L, FU X H, YU Y, et al. Treatment with CA-074Me, a Cathepsin B inhibitor, reduces lung interstitial inflammation and fibrosis in a rat model of polymyositis[J]. Lab Invest, 2015, 95(1):65-77. doi:10.1038/labinvest.2014.135.
[28]	KOSLOWSKI R, KNOCH K, KUHLISCH E, et al. Cathepsins in bleomycin-induced lung injury in rat[J]. Eur Respir J, 2003, 22(3):427-435. doi:10.1183/09031936.03.00112903.
[29]	GRAMAGLIA I, JEMBER A, PIPPIG S D, et al. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion[J]. J Immunol, 2000, 165(6):3043-3050. doi:10.4049/jimmunol.165.6.3043.
[30]	ZAIZEN Y, OKAMOTO M, AZUMA K, et al. Enhanced immune complex formation in the lungs of patients with dermatomyositis[J]. Respir Res, 2023, 24(1):86. doi:10.1186/s12931-023-02362-0.
[31]	HOSHINO T, KATO S, OKA N, et al. Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13[J]. Am J Respir Crit Care Med, 2007, 176(1):49-62. doi:10.1164/rccm.200603-316OC.